Hepatocellular adenoma risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}};{{AE}} {{ZAS}} | {{CMG}};{{AE}} {{ZAS}} | ||
==Overview== | ==Overview== | ||
The most important [[risk factor]] | The most important [[risk factor]] for the development of hepatocellular adenoma is the use of [[Oral contraceptive|oral contraceptive medications]]. Other [[Risk factor|risk factors]] include [[Glycogen storage disease|glycogen storage diseases]], [[familial adenomatous polyposis]], [[Klinefelter's syndrome]], [[metabolic syndrome]], [[obesity]], long term use of [[anabolic]] [[androgenic]] [[steroids]], [[vascular disorders]] such as [[portal vein]] [[agenesis]], [[Budd-Chiari syndrome]], and [[hereditary hemorrhagic telangiectasia]]. | ||
== | ==Risk Factors== | ||
* The most important [[risk factor]] | * The most important [[risk factor]] for the development of hepatocellular adenoma is the use of [[Oral contraceptive|oral contraceptive medications]], such as:<ref>{{Cite journal | ||
| author = [[L. Rosenberg]] | | author = [[L. Rosenberg]] | ||
| title = The risk of liver neoplasia in relation to combined oral contraceptive use | | title = The risk of liver neoplasia in relation to combined oral contraceptive use | ||
| Line 17: | Line 17: | ||
| pmid = 1651205 | | pmid = 1651205 | ||
}}</ref> | }}</ref> | ||
:*[[Drospirenone and Ethinyl estradiol]] | :*[[Drospirenone and Ethinyl estradiol]] | ||
:*[[Norethindrone acetate and Ethinyl estradiol]] | :*[[Norethindrone acetate and Ethinyl estradiol]] | ||
| Line 22: | Line 23: | ||
:*[[Norgestrel and Ethinyl estradiol]] | :*[[Norgestrel and Ethinyl estradiol]] | ||
:* The risk is proportional to:<ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref> | :* The risk is proportional to:<ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref> | ||
:* [[Hormone|Hormonal]] [[dose]] | |||
:* Duration of [[medication]] | |||
* Other [[Risk factor|risk factors]] include:<ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref><ref>{{Cite journal | * Other [[Risk factor|risk factors]] include:<ref name="pmid18333188">{{cite journal| author=Barthelmes L, Tait IS| title=Liver cell adenoma and liver cell adenomatosis. | journal=HPB (Oxford) | year= 2005 | volume= 7 | issue= 3 | pages= 186-96 | pmid=18333188 | doi=10.1080/13651820510028954 | pmc=PMC2023950 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18333188 }} </ref><ref>{{Cite journal | ||
| author = [[U. Beuers]], [[W. O. Richter]], [[M. M. Ritter]], [[B. Wiebecke]] & [[P. Schwandt]] | | author = [[U. Beuers]], [[W. O. Richter]], [[M. M. Ritter]], [[B. Wiebecke]] & [[P. Schwandt]] | ||
| Line 62: | Line 63: | ||
:* [[Familial adenomatous polyposis]] | :* [[Familial adenomatous polyposis]] | ||
==Risk | ===Risk Factors for Malignant Transformation=== | ||
[[risk factor|Risk factors]] for the [[malignant transformation]] of hepatocellular adenoma to [[hepatocellular carcinoma]] include:<ref name="pmid25786843">{{cite journal| author=Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H| title=[Hepatocellular adenoma - new classification and recommendations]. | journal=Ugeskr Laeger | year= 2015 | volume= 177 | issue= 12 | pages= | pmid=25786843 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25786843 }} </ref> | |||
:* Gender (men) | :* Gender (men) | ||
:* Size (> 8 cm) | :* Size (> 8 cm) | ||
:* | :* Sub-type (''[[beta-catenin]]''-activated hepatocellular adenoma) | ||
==References== | ==References== | ||
Latest revision as of 21:07, 20 August 2019
|
Hepatocellular adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatocellular adenoma risk factors On the Web |
|
American Roentgen Ray Society Images of Hepatocellular adenoma risk factors |
|
Risk calculators and risk factors for Hepatocellular adenoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Overview
The most important risk factor for the development of hepatocellular adenoma is the use of oral contraceptive medications. Other risk factors include glycogen storage diseases, familial adenomatous polyposis, Klinefelter's syndrome, metabolic syndrome, obesity, long term use of anabolic androgenic steroids, vascular disorders such as portal vein agenesis, Budd-Chiari syndrome, and hereditary hemorrhagic telangiectasia.
Risk Factors
- The most important risk factor for the development of hepatocellular adenoma is the use of oral contraceptive medications, such as:[1]
- Drospirenone and Ethinyl estradiol
- Norethindrone acetate and Ethinyl estradiol
- Norgestimate and Ethinyl estradiol
- Norgestrel and Ethinyl estradiol
- The risk is proportional to:[2]
- Hormonal dose
- Duration of medication
- Other risk factors include:[2][3][4][5]
Risk Factors for Malignant Transformation
Risk factors for the malignant transformation of hepatocellular adenoma to hepatocellular carcinoma include:[6]
- Gender (men)
- Size (> 8 cm)
- Sub-type (beta-catenin-activated hepatocellular adenoma)
References
- ↑ L. Rosenberg (1991). "The risk of liver neoplasia in relation to combined oral contraceptive use". Contraception. 43 (6): 643–652. PMID 1651205. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 Barthelmes L, Tait IS (2005). "Liver cell adenoma and liver cell adenomatosis". HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
- ↑ U. Beuers, W. O. Richter, M. M. Ritter, B. Wiebecke & P. Schwandt (1991). "Klinefelter's syndrome and liver adenoma". Journal of clinical gastroenterology. 13 (2): 214–216. PMID 1851773. Unknown parameter
|month=ignored (help) - ↑ N. S. Alshak, J. Cocjin, L. Podesta, R. van de Velde, L. Makowka, P. Rosenthal & S. A. Geller (1994). "Hepatocellular adenoma in glycogen storage disease type IV". Archives of pathology & laboratory medicine. 118 (1): 88–91. PMID 8285839. Unknown parameter
|month=ignored (help) - ↑ S. Bala, P. H. Wunsch & W. G. Ballhausen (1997). "Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53". Gastroenterology. 112 (3): 919–922. PMID 9041254. Unknown parameter
|month=ignored (help) - ↑ Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H (2015). "[Hepatocellular adenoma - new classification and recommendations]". Ugeskr Laeger. 177 (12). PMID 25786843.